JG
IOVA icon

Jefferies Group’s Iovance Biotherapeutics IOVA Stock Holding History

Jefferies Group’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-121
Closed -$1.34K – 1783
2022
Q2 		$1.34K Buy
+121
New +$1.59K ﹤0.01% 1503
2022
Q1 		– Sell
-16,056
Closed -$307K – 1724
2021
Q4 		$307K Buy
+16,056
New +$353K ﹤0.01% 1293
2021
Q3 		– Sell
-370,260
Closed -$9.63M – 1854
2021
Q2 		$9.63M Buy
370,260
+351,760
+1,901% +$9.14M 0.06% 283
2021
Q1 		$586K Sell
18,500
-460,000
-96% -$19.1M 0.01% 1078
2020
Q4 		$22.2M Buy
+478,500
New +$19M 0.17% 96
2020
Q3 		– Sell
-9,757
Closed -$268 – 1444
2020
Q2 		$268 Sell
9,757
-61,871
-86% -$2.03M ﹤0.01% 1030
2020
Q1 		$2.14M Buy
71,628
+71,128
+14,226% +$1.89M 0.02% 657
2019
Q4 		$14K Sell
500
-15,835
-97% -$360K ﹤0.01% 2487
2019
Q3 		$297K Buy
+16,335
New +$361K ﹤0.01% 2188
2018
Q2 		– Sell
-25,000
Closed -$423K – 2488
2018
Q1 		$423K Buy
+25,000
New +$379K ﹤0.01% 1594
2016
Q1 		– Sell
-491
Closed -$4K – 2398
2015
Q4 		$4K Buy
+491
New +$3.41K ﹤0.01% 2215

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Jefferies Group's IOVA Position: Q3 2022 in Review

Jefferies Group sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 121 shares — an estimated $1.34K sold.

Jefferies Group first reported a position in IOVA in Q4 2015 and held it in 11 quarters. The position peaked at $22.2M in Q4 2020. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

  • Jefferies Group reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 121 Iovance Biotherapeutics shares in Q3 2022, an estimated $1.34K.
  • Jefferies Group first reported a position in Iovance Biotherapeutics in Q4 2015 and held it in 11 quarters.
  • Jefferies Group's Iovance Biotherapeutics position peaked at $22.2M in Q4 2020.
  • 242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.